Πέμπτη 9 Φεβρουαρίου 2017

Severe hepatitis arising from ipilimumab administration, following melanoma treatment with nivolumab.

Related Articles

Severe hepatitis arising from ipilimumab administration, following melanoma treatment with nivolumab.

Jpn J Clin Oncol. 2017 Feb 11;47(2):175-178

Authors: Tanaka R, Fujisawa Y, Sae I, Maruyama H, Ito S, Hasegawa N, Sekine I, Fujimoto M

PMID: 28173241 [PubMed - in process]



http://ift.tt/2lu8AXS

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου